Literature DB >> 23211650

Obstructive sleep apnea can be safely managed in a level 2 critical care setting after laparoscopic bariatric surgery.

Euan Shearer1, Conor J Magee, Carmen Lacasia, David Raw, David Kerrigan.   

Abstract

BACKGROUND: In the United Kingdom, demand for intensive care beds (level 3 critical care) often outstrips supply, leading to frequent and frustrating cancellation of complex elective surgery. It has been suggested that patients with obstructive sleep apnea who undergo bariatric surgery should be admitted to a level 3 facility for routine postoperative management. We have questioned the validity of this dogma in the era of laparoscopic bariatric surgery by using a simple easily applicable algorithm.
OBJECTIVES: The aim of this study was to investigate the clinical outcome of patients with obstructive sleep apnea (OSA) without admission to the intensive care unit after laparoscopic bariatric surgery.
METHODS: For the first 24 hours after surgery, all patients were admitted to a level 2 (high-dependency) area on a general surgical ward with experience of bariatric surgery. They received supplemental oxygen, continuous pulse oximetry, and judicious analgesic administration using a combination of small boluses of i.v. morphine together with i.v. paracetamol. Perioperative continuous positive airway pressure support was not routinely given, unless patients with OSA had oxygen saturation below their recorded preoperative level on 2 consecutive readings.
RESULTS: A total of 1623 patients underwent laparoscopic bariatric surgery over a 12-year period. Of those, 192 had OSA with a median operative body mass index of 52 kg/m(2) (range 34-78 kg/m(2)). The incidence of respiratory complications and the median length of stay (3 nights) were identical in patients with OSA and those without OSA. Four patients self-administered perioperative continuous positive airway pressure, but none required transfer to intensive care or mechanical ventilation. There were no in-hospital deaths.
CONCLUSION: Laparoscopic bariatric surgery in patients with OSA is well tolerated and does not require the routine use of level 3 critical care facilities. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric; Laparoscopic; Safety; Sleep apnea

Mesh:

Year:  2012        PMID: 23211650     DOI: 10.1016/j.soard.2012.09.006

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  4 in total

Review 1.  [Tracheotomy or planned prolonged intubation after surgery for patients with OSAS].

Authors:  H P Zenner
Journal:  HNO       Date:  2014-10       Impact factor: 1.284

2.  Routine Postoperative Monitoring after Bariatric Surgery in Morbidly Obese Patients with Severe Obstructive Sleep Apnea: ICU Admission is not Necessary.

Authors:  Amin B Goucham; Usha K Coblijn; Helga B Hart-Sweet; Nico de Vries; Sjoerd M Lagarde; Bart A van Wagensveld
Journal:  Obes Surg       Date:  2016-04       Impact factor: 4.129

3.  Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP.

Authors:  Nicola Di Lorenzo; Stavros A Antoniou; Rachel L Batterham; Luca Busetto; Daniela Godoroja; Angelo Iossa; Francesco M Carrano; Ferdinando Agresta; Isaias Alarçon; Carmil Azran; Nicole Bouvy; Carmen Balaguè Ponz; Maura Buza; Catalin Copaescu; Maurizio De Luca; Dror Dicker; Angelo Di Vincenzo; Daniel M Felsenreich; Nader K Francis; Martin Fried; Berta Gonzalo Prats; David Goitein; Jason C G Halford; Jitka Herlesova; Marina Kalogridaki; Hans Ket; Salvador Morales-Conde; Giacomo Piatto; Gerhard Prager; Suzanne Pruijssers; Andrea Pucci; Shlomi Rayman; Eugenia Romano; Sergi Sanchez-Cordero; Ramon Vilallonga; Gianfranco Silecchia
Journal:  Surg Endosc       Date:  2020-04-23       Impact factor: 4.584

Review 4.  Patients with sleep-disordered breathing for bariatric surgery.

Authors:  Matthew W Oh; Joy L Chen; Tiffany S Moon
Journal:  Saudi J Anaesth       Date:  2022-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.